Lifecare ASA

Regulatory Filings • Dec 16, 2025

Lifecare implants first consistently manufactured implant

Lifecare implants first consistently manufactured implant

Bergen, Norway, 16 December 2025 - Lifecare ASA (LIFE), a MedTech company

developing next-generation implantable Continuous Glucose Monitoring (CGM)

technology, today announces that the first implant from a new production batch

has been successfully implanted, marking an important step in demonstrating

manufacturing reproducibility and process control under the company's updated

production protocol.

The manufacturing milestone relates to the full implantable product,

integrating Lifecare's proprietary sensing technology with electronics,

wireless communication and encapsulation into a medical-grade device designed

for implantation. While Lifecare has previously demonstrated the ability to

produce individual sensor components, the ability to reproducibly manufacture

the complete implant as a functional and implantable product represents a

significant step forward in the company's development.

The implant, delivered by Lifecare's development partner TTP plc, successfully

completed laboratory testing, functional handover testing, sterilisation and

sterility confirmation prior to implantation on 9 December 2025 at the Faculty

of Veterinary Medicine, Department of Companion Animal Clinical Sciences at

the Norwegian University of Life Sciences (NMBU).

Following implantation, electrical functionality and communication with the

external read-out device (collar) have been confirmed. The implant is now

being monitored in accordance with Lifecare's established study protocol.

"This milestone is important for several reasons," says Joacim Holter, CEO of

Lifecare. "Our sensing technology has previously demonstrated reliable glucose

responsiveness in humans, and this has again been confirmed through laboratory

testing. What is particularly significant at this stage is that these results

are now achieved using an improved implant manufactured as a complete product

under our updated production protocol. This marks a clear transition from

validating the underlying technology to demonstrating our ability to

reproducibly manufacture high-quality, implantable devices in a controlled and

repeatable manner, incorporating the improvements we have made across design,

materials and production."

The implantation represents the first use of Lifecare's most advanced implant

generation to date in a live tissue setting, manufactured under the updated

protocol. Additional fully functional implants from the same production batch

have been manufactured and tested under Lifecare's updated production protocol

and are planned for use in further implantations as part of Lifecare's ongoing

trial.

This development represents a key step in Lifecare's transition from

technology development to execution, supporting continued progress toward

veterinary market entry and future clinical programs.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42